#ASCO21 #ASCO2021 plenaries

LBA 1 Breast - adjuvant PARPi in BRCA+
LBA 2 NPC - addition of IO to chemo
LBA 3 Cervix - adj chemo following chemoRT
LBA 4 Prostate - theranostics - ph 3 Lu-PSMA
LBA 5 Renal - adj IO post nephrectomy

LBA1 OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

LBA2 JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

LBA3 Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Go @ANZGOG !!!

LBA4 Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

LBA 5
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.